Dx & Vx Co., Ltd. (180400.KQ)
KOSDAQ · KRW · Healthcare · Diagnostics & Research
₩1,896 (-0.78%) as of
Key statistics
- Market cap
- 186.62B
- Dividend yield
- 0.00%
- 52-week range
- 1,319.00 – 5,360.00
- Beta
- 0.01
- Revenue (TTM)
- 26.22B
- Profit margin
- -96.17%
- Volume
- 52.49k
About Dx & Vx Co., Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs. Its pipeline includes Vx product, oral pediatric Covid19/influenza vaccine; new anti-cancer antibody drug; an antibody drug utilizing advanced mRNA vaccine development technique; Vx Microbiome R&D pipeline, a bacterial vaccine against respiratory diseases, new drugs targeting obesity and diagnosis etc; and Oxford Vacmedix Vaccine, an anti-cancer vaccineutilizing ROP technology. It has a research collaboration with bereum, Bioapp, CORESTEMCHEMON, Genscript PROBIO, JOINTOWN PHARMACEUTICAL GROUP,etc. The company was formerly known as Cancer Rop Co., Ltd. and changed its name to Dx & Vx Co., Ltd. in January 2022. The company was founded in 2001 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Seoul, South Korea
- Employees
- 82
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.